Skip to main content

Advertisement

SpringerLink
Log in

Prospective trial of treat-and-extend regimen with aflibercept for branch retinal vein occlusion: 1-year results of the PLATON trial

  • Retinal Disorders
  • Published:
Graefe's Archive for Clinical and Experimental Ophthalmology Aims and scope Submit manuscript

Abstract

Purpose

To evaluate the functional and anatomical outcomes of a treat-and-extend (TAE) regimen with aflibercept for treatment-naive macular edema (ME) secondary to branch retinal vein occlusion (BRVO).

Methods

This was a prospective, multicenter, noncomparative, open-label clinical trial. Forty-eight eyes of 48 patients received three monthly intravitreal aflibercept injections prior to the TAE regimen. However, if the best-corrected visual acuity (BCVA) was ≥ 20/20 and the central macular thickness (CMT) was < 250 μm during the loading phase, the patient immediately proceeded to the TAE regimen. The treatment interval was adjusted by 4 weeks based on changes in CMT. The primary outcome was the mean change in BCVA from baseline to 52 weeks.

Results

The mean change in BCVA was 23.6 ± 14.2 letters. The proportion of patients with BCVA gain ≥ 15 letters was 77.1% at 24 weeks and 72.9% at 52 weeks. The mean reduction in CMT was 326.2 ± 235.6 μm at 24 weeks and 324.2 ± 238.0 μm at 52 weeks. The mean number of injections was 6.7 ± 1.2 (range: 6–11, all patients received three monthly intravitreal aflibercept injections) over 52 weeks, and 34 patients (70.8%) reached the maximal extension interval of 16 weeks at 52 weeks.

Conclusions

The TAE regimen using aflibercept for ME secondary to BRVO, which has a treatment interval of up to 16 weeks, showed comparable efficacy to the fixed-dosing regimen along with reduced treatment burden.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Rogers S, McIntosh RL, Cheung N et al (2010) The prevalence of retinal vein occlusion: pooled data from population studies from the United States, Europe, Asia, and Australia. Ophthalmology 117(2):313–19. e1

    Article  Google Scholar 

  2. Klein R, Moss SE, Meuer SM et al (2008) The 15-year cumulative incidence of retinal vein occlusion: the Beaver Dam Eye Study. Arch Ophthalmol 126(4):513–518

    Article  Google Scholar 

  3. Rehak M, Wiedemann P (2010) Retinal vein thrombosis: pathogenesis and management. J Thromb Haemost 8(9):1886–1894

    Article  CAS  Google Scholar 

  4. Rehak J, Rehak M (2008) Branch retinal vein occlusion: pathogenesis, visual prognosis, and treatment modalities. Curr Eye Res 33(2):111–131

    Article  Google Scholar 

  5. Campochiaro PA, Heier JS, Feiner L et al (2010) Ranibizumab for macular edema following branch retinal vein occlusion: six-month primary end point results of a phase III study. Ophthalmology 117(6):1102–12. e1

    Article  Google Scholar 

  6. Brown DM, Campochiaro PA, Bhisitkul RB et al (2011) Sustained benefits from ranibizumab for macular edema following branch retinal vein occlusion: 12-month outcomes of a phase III study. Ophthalmology 118(8):1594–1602

    Article  Google Scholar 

  7. Campochiaro PA, Clark WL, Boyer DS et al (2015) Intravitreal aflibercept for macular edema following branch retinal vein occlusion: the 24-week results of the VIBRANT study. Ophthalmology 122(3):538–544

    Article  Google Scholar 

  8. Clark WL, Boyer DS, Heier JS et al (2016) Intravitreal aflibercept for macular edema following branch retinal vein occlusion: 52-week results of the VIBRANT study. Ophthalmology 123(2):330–336

    Article  Google Scholar 

  9. Holash J, Davis S, Papadopoulos N et al (2002) VEGF-Trap: a VEGF blocker with potent antitumor effects. Proc Natl Acad Sci U S A 99(17):11393–11398

    Article  CAS  Google Scholar 

  10. Stewart MW, Rosenfeld PJ (2008) Predicted biological activity of intravitreal VEGF Trap. Br J Ophthalmol 92(5):667–668

    Article  CAS  Google Scholar 

  11. Heier JS, Campochiaro PA, Yau L et al (2012) Ranibizumab for macular edema due to retinal vein occlusions: long-term follow-up in the HORIZON trial. Ophthalmology 119(4):802–809

    Article  Google Scholar 

  12. Campochiaro PA, Sophie R, Pearlman J et al (2014) Long-term outcomes in patients with retinal vein occlusion treated with ranibizumab: the RETAIN study. Ophthalmology 121(1):209–219

    Article  Google Scholar 

  13. Campochiaro PA, Wykoff CC, Singer M et al (2014) Monthly versus as-needed ranibizumab injections in patients with retinal vein occlusion: the SHORE study. Ophthalmology 121(12):2432–2442

    Article  Google Scholar 

  14. Tadayoni R, Waldstein SM, Boscia F et al (2016) Individualized stabilization criteria–driven ranibizumab versus laser in branch retinal vein occlusion: six-month results of BRIGHTER. Ophthalmology 123(6):1332–1344

    Article  Google Scholar 

  15. Chatziralli I, Theodossiadis G, Chatzirallis A et al (2018) Ranibizumab for retinal vein occlusion: predictive factors and long-term outcomes in real-life data. Retina 38(3):559–568

    Article  CAS  Google Scholar 

  16. Scott IU, VanVeldhuisen PC, Ip MS et al (2018) Comparison of monthly vs treat-and-extend regimens for individuals with macular edema who respond well to anti-vascular endothelial growth factor medications: secondary outcomes from the SCORE2 randomized clinical trial. JAMA Ophthalmol 136(4):337–345

    Article  Google Scholar 

  17. Guichard M-M, Xavier AR, Türksever C et al (2018) Spectral-domain optical coherence tomography-driven treat-and-extend and pro re nata regimen in patients with macular oedema due to retinal vein occlusion: 24-month evaluation and outcome predictors. Ophthalmic Res 60(1):29–37

    Article  Google Scholar 

  18. Yiu G, Welch RJ, Wang Y et al (2020) Spectral-domain OCT predictors of visual outcomes after ranibizumab treatment for macular edema resulting from retinal vein occlusion. Ophthalmol Retina 4(1):67–76

    Article  Google Scholar 

  19. Sırakaya E, Küçük B, Ağadayı A (2020) Aflibercept treatment for macular edema following branch retinal vein occlusion: age-based responses. Ophthalmologica 243(2):93–100

    Article  Google Scholar 

  20. Jaissle GB, Szurman P, Feltgen N et al (2011) Predictive factors for functional improvement after intravitreal bevacizumab therapy for macular edema due to branch retinal vein occlusion. Graefes Arch Clin Exp Ophthalmol 249(2):183–192

    Article  CAS  Google Scholar 

  21. Chung EJ, Hong YT, Lee SC et al (2008) Prognostic factors for visual outcome after intravitreal bevacizumab for macular edema due to branch retinal vein occlusion. Graefes Arch Clin Exp Ophthalmol 246(9):1241–1247

    Article  CAS  Google Scholar 

  22. de Salles MC, Amrén U, Kvanta A et al (2019) Injection frequency of aflibercept versus ranibizumab in a treat-and-extend regimen for central retinal vein occlusion: a randomized clinical trial. Retina 39(7):1370–1376

    Article  Google Scholar 

Download references

Funding

This study was funded by Bayer Korea. The sponsor provided study drug and participated in review of the manuscript.

Author information

Authors and Affiliations

  1. Department of Ophthalmology, Yeungnam University College of Medicine, #170 Hyunchungro, Nam-gu, Daegu, 42415, South Korea

    Dong-Geun Park & Min Sagong

  2. Department of Ophthalmology, Dong-A University College of Medicine, Busan, South Korea

    Woo Jin Jeong

  3. Department of Ophthalmology, Maryknoll General Hospital, Busan, South Korea

    Jung Min Park

  4. Department of Ophthalmology, Chungnam National University College of Medicine, Daejeon, South Korea

    Jung-Yeul Kim

  5. Department of Ophthalmology, Chonnam National University Medical School and Hospital, Gwangju, South Korea

    Yong-Sok Ji

Authors
  1. Dong-Geun Park
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Woo Jin Jeong
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jung Min Park
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Jung-Yeul Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Yong-Sok Ji
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Min Sagong
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Min Sagong.

Ethics declarations

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional review board (Yeungnam University Hospital IRB, Daegu, South Korea; Dong-A University Hospital IRB, Busan, South Korea; Chungnam National University Hospital IRB, Daejeon, South Korea; Maryknoll General Hospital IRB, Busan, South Korea; Chonnam National University Hospital IRB, Gwangju, South Korea), and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Informed consent

Informed consent was obtained from all individual participants included in the study.

Conflict of interest

Author D.P. authors certify that they have no affiliations with or involvement in any organization or entity with any financial interest, or non-financial interest in the subject matter or materials discussed in this manuscript. Author W.J. received a research grant from Bayer. Author J.P. received a research grant from Bayer. Author J.K. received a research grant from Bayer. Author Y.J. received a research grant from Bayer. Author M.S. received a research grant from Bayer, Novartis, and Allergan.

Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Park, DG., Jeong, W.J., Park, J.M. et al. Prospective trial of treat-and-extend regimen with aflibercept for branch retinal vein occlusion: 1-year results of the PLATON trial. Graefes Arch Clin Exp Ophthalmol 259, 2879–2886 (2021). https://doi.org/10.1007/s00417-021-05150-y

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00417-021-05150-y

Keywords

Search

Navigation